RE:RE:NGM down 70% pre-marketAccept the point, but important to note the NGM drug was for a rare ocular disease and it was not a similar type of construct or approach to an oncology PDC or even ADC. Just don't want folks here to look at that as a direct analogy around PDCs as opposed to the general biotech trial analogy that it is.
I still like the fact that we appear to have safety issues within normal boundaries for an oncology trial and the active ingredient is well known and generic --we just need to get proof the delivery system is working, effective, and the reason it's helping the target population where others have failed.
Biobob wrote: Well it works both way... Th1902 had maybe 25% downside in the price atm and 100%+ upside in the shorterm and 10 bagger potential in the medium term.. and we shall see once where there in the long term...